Best Antithrombotic Therapy in patients with acute Venous ThromboEmbolism while taking antiplatelets: the BAT-VTE - 20PH285

CHU De Saint Etienne0 个研究点目标入组 1,400 人开始时间: 2022年12月6日最近更新: 2024年7月22日

适应症

试验速览

暂无简介。

•Patients with acute objectively confirmed symptomatic proximal deep-vein thrombosis (DVT) or pulmonary embolism (PE) (with or without deep-vein thrombosis). Proximal deep-vein thrombosis is defined as thrombosis involving at least the popliteal vein or a more proximal vein of the lower limb., Indication of full-dose anticoagulant therapy for at least 3 months., Prescription of antiplatelet therapy for secondary prevention of atherosclerotic cardiovascular diseases, at the time of VTE diagnosis

•Active bleeding or a high risk of bleeding contraindicating anticoagulant treatment; a systolic blood pressure of more than 180 mm Hg or a diastolic blood pressure of more than 110 mm Hg, Anticoagulation for more than 5 days prior to randomization, Active pregnancy or expected pregnancy or no effective contraception, Isolated distal deep vein thrombosis, Antiplatelet therapy prescribed for primary prevention of cardiovascular disease, Indication to maintain a dual-antiplatelet therapy, Triple positive antiphospholipide syndrome, with arterial thrombosis, Major cardiovascular and cerebrovascular event in the past 12 months for acute coronary syndrom, and in the past 6 months for cerebrovascular diseases and peripheral arterial diseases, Isolated sub-segmental pulmonary embolism

发起方

CHU De Saint Etienne